The aim of this literature study is to evaluate the various endocrine drugs used in the treatment of
breast cancer in order to compare their therapeutic efficacy.
Hormone-dependent metastasized
breast cancer of post-menopausal women can be treated with four equivalent drugs:
tamoxifen,
megestrol,
medroxyprogesterone, and--combined with
steroid suppletion
therapy--
aminoglutethimide. Each of these drugs induces (partial) remissions in 50-60% of
estrogen receptor-positive
tumors. Because of its relatively few and less serious side-effects
tamoxifen is the agent of first choice for soft tissue and lung
metastases. Due to its potentially enhanced objective and more pronounced subjective side-effects,
aminoglutethimide may be preferred in bone
metastases. In view of the only minor activity of hormonal agents in liver
metastases,
combination chemotherapy with concomitant, sequential or alternating use of hormonal agents should be considered in this condition. Until now, only
tamoxifen seems suitable for the treatment of premenopausal metastasized
hormone-dependent
breast cancer. In the adjuvant setting, preoperatively initiated and as soon as possible postoperatively continued endocrine
therapy seems to be of the utmost importance to counteract (occult)
metastases while reducing the need for extensive surgery.